In silico classification of hERG channel blockers: A knowledge-based strategy

ChemMedChem

Volumn 1, Issue 6, 2006, Pages 622-630

  Dubus, Elodie ^a   Ijjaali, Ismail ^a   Petitet, François ^a   Michel, André ^a  

^a Aureus Pharma   (France)

Author keywords

Computer chemistry; hERG; Molecular modeling; QT interval prolongation; Recursive partitioning

Indexed keywords

ERG1 POTASSIUM CHANNEL; KCNH2 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG;

ARTICLE; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG DESIGN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746275630     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200500099     Document Type: Article

References (30)

1. a) Y. G. Yap, A. J. Camm, Heart 2003, 89, 1363-1372;
2. b) I. Cavero, M. Mestre, J.-M. Guillon, W. Crumb, Expert Opin. Pharmacother. 2000, 1, 947-973.
3. K. Finlayson, H. J. Witchel, J. McCulloch, J. Sharkey, Eur. J. Pharmacol. 2004, 500, 129-142.
4. M. Recanatini, E. Poluzzi, M. Masetti, A. Cavalli, F. De Ponti, Med. Res. Rev. 2005, 25, 133-166.
5. J. Tamargo, Jpn. J. Pharmacol. 2000, 83, 1-19.
6. a) M. C. Sanguinetti, J. S. Mitcheson, Trends Pharmacol. Sci. 2005, 26, 119-124;
7. b) A. M. Aronov, Drug Discovery Today 2005, 10, 149-155.
8. J. S. Mitcheson, J. Chen, M. Lin, C. Culberson, M. C. Sanguinetti, Proc. Natl. Acad. Sci. USA 2000, 97, 12329-12333.
9. R. A. Pearlstein, R. J. Vaz, J. Kang, X. L. Chen, M. Preobrazhenskaya, A. E. Shchekotikhin, A. M. Korolev, L. N. Lysenkova, O. V. Miroshnikova, J. Hendrix, D. Rampe, Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835.
10. A. Cavalli, E. Poluzzi, F. De Ponti, M. Recanatini, J. Med. Chem. 2002, 45, 3844-3853.
11. S. Ekins, W. J. Crumb, R. D. Sarazan, J. H. Wikel, S. A. Wrighton, J. Pharmacol. Exp. Ther. 2002, 301, 427-434.
12. a) R. Rajamani, B. A. Tounge, J. Li, C. H. Reynolds, Bioorg. Med. Chem. Lett. 2005, 15, 1737-1741;
13. b) G. Cianchetta, Y. Li, J. Kang, D. Rampe, A. Fravolini, G. Cruciani, R. J. Vaz, Bioorg. Med. Chem. Lett. 2005, 15, 3637-3642.
14. G. M. Keserü, Bioorg. Med. Chem. Lett. 2003, 13, 2773-2775.
15. A. M. Aronov, B. B. Goldman, Bioorg. Med. Chem. 2004, 12, 2307-2315.
16. O. Roche, G. Trube, J. Zuegge, P. Pflimlin, A. Alanine, G. Schneider, ChemBioChem 2002, 3, 455-459.
17. M. Tobita, T. Nishikawa, R. Nagashima, Bioorg. Med. Chem. Lett. 2005, 15, 2886-2890.
18. R. G. Susnow, S. L. Dixon, J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
19. N. Baurin, J.-C. Mozziconacci, E. Arnoult, P. Chavatte, C. Marot, L. Worin-Allory, J. Chem. Inf. Comput Sci. 2004, 44, 276-285.
20. A. Rusinko, M. W. Farmen, C. G. Lambert, P. L. Brown, S. S. Young, J. Chem. Inf. Comput. Sci. 1999, 39, 1017-1026.
21. C. Buyck in EuroQSAR 2002. Designing Drugs and Crop Protectants: Processes, Problems, and Solutions (Eds.: M. Ford, D. Livingstone, J. Dearden, H. Van der Waterbeemd), Blackwell, Oxford, 2003, pp. 86-89.
22. Aureus Pharma, Paris, France, http://www.aureus-pharma.com.
23. JChem, version 3.0.10, ChemAxon, Budapest, Hungary, http://www. chemaxon.com.
24. MOE (Molecular Operating Environment), version 2004.03, Chemical Computing Group Inc., Montreal, Canada, http://www.chemcomp.com.
25. P. Labute, J. Mol. Graphics Modell. 2000, 18, 464-477.
26. J. Gasteiger, M. Marsili, Tetrahedron 1980, 36, 3219-3228.
27. M. A. Hall, PhD thesis, Waikato University, New Zealand, 1999.
28. Specs, Delft, Holland, http://www.specs.net.
29. P. E. Blower, K. P. Cross, M. A. Fligner, G. J. Myatt, J. S. Verducci, C. Yang, Curr. Drug Discovery Technol. 2004, 1, 37-47.
30. D. Fernandez, A. Ghanta, G. W. Kauffman, M. C. Sanguinetti, J. Biol. Chem. 2004, 279, 10120-10127.